Tags

Type your tag names separated by a space and hit enter

SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
Oncogene. 2015 Jan 29; 34(5):631-8.O

Abstract

Constitutional dominant loss-of-function mutations in the SPRED1 gene cause a rare phenotype referred as neurofibromatosis type 1 (NF1)-like syndrome or Legius syndrome, consisted of multiple café-au-lait macules, axillary freckling, learning disabilities and macrocephaly. SPRED1 is a negative regulator of the RAS MAPK pathway and can interact with neurofibromin, the NF1 gene product. Individuals with NF1 have a higher risk of haematological malignancies. SPRED1 is highly expressed in haematopoietic cells and negatively regulates haematopoiesis. SPRED1 seemed to be a good candidate for leukaemia predisposition or transformation. We performed SPRED1 mutation screening and expression status in 230 paediatric lymphoblastic and acute myeloblastic leukaemias (AMLs). We found a loss-of-function frameshift SPRED1 mutation in a patient with Legius syndrome. In this patient, the leukaemia blasts karyotype showed a SPRED1 loss of heterozygosity, confirming SPRED1 as a tumour suppressor. Our observation confirmed that acute leukaemias are rare complications of the Legius syndrome. Moreover, SPRED1 was significantly decreased at RNA and protein levels in the majority of AMLs at diagnosis compared with normal or paired complete remission bone marrows. SPRED1 decreased expression correlated with genetic features of AML. Our study reveals a new mechanism which contributes to deregulate RAS MAPK pathway in the vast majority of paediatric AMLs.

Authors+Show Affiliations

1] UMR_S745 INSERM, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes Sorbonne Paris Cité, Paris, France [2] Service de Biochimie et Génétique Moléculaire, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.Service de Génétique, C.H.U. de Poitiers, Poitiers, France.1] Service d'Hématologie-Oncologie, Hôpital A Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Université Pierre et Marie Curie Paris 6, Paris, France [3] UMR938, Université Paris 6, Pierre et Marie Curie, Paris, France.INSERM 1016, Institut Cochin, CNRS UMR8104, Université Paris Descartes, Paris, France.1] UMR_S745 INSERM, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes Sorbonne Paris Cité, Paris, France [2] Service de Biochimie et Génétique Moléculaire, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.UMR_S745 INSERM, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes Sorbonne Paris Cité, Paris, France.1] UMR938, Université Paris 6, Pierre et Marie Curie, Paris, France [2] Service d'Hématologie Biologique, Hôpital Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France.1] Service d'Hématologie-Oncologie, Hôpital A Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Université Pierre et Marie Curie Paris 6, Paris, France [3] UMR938, Université Paris 6, Pierre et Marie Curie, Paris, France.Service de Biochimie et Génétique Moléculaire, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.UMR_S745 INSERM, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes Sorbonne Paris Cité, Paris, France.UMR967, CEA, Université Paris 7, Fontenay aux Roses, France.UMR967, CEA, Université Paris 7, Fontenay aux Roses, France.Laboratoire d'Hématologie Biologique, C.H.U. de Poitiers, Poitiers, France.Service de Dermatologie, C.H.U. de Dijon et EA 4271, Université de Bourgogne, France.UMR967, CEA, Université Paris 7, Fontenay aux Roses, France.1] Service d'Hématologie-Oncologie, Hôpital A Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Université Pierre et Marie Curie Paris 6, Paris, France.Service de Pédiatrie, C.H.U de Poitiers, Poitiers, France.INSERM 1016, Institut Cochin, CNRS UMR8104, Université Paris Descartes, Paris, France.1] UMR_S745 INSERM, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes Sorbonne Paris Cité, Paris, France [2] Service de Biochimie et Génétique Moléculaire, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France [3] Service de Génétique, C.H.U. de Poitiers, Poitiers, France.1] Service d'Hématologie-Oncologie, Hôpital A Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Université Pierre et Marie Curie Paris 6, Paris, France [3] UMR938, Université Paris 6, Pierre et Marie Curie, Paris, France.Service d'Hématologie Biologique, Hôpital Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24469042

Citation

Pasmant, E, et al. "SPRED1, a RAS MAPK Pathway Inhibitor That Causes Legius Syndrome, Is a Tumour Suppressor Downregulated in Paediatric Acute Myeloblastic Leukaemia." Oncogene, vol. 34, no. 5, 2015, pp. 631-8.
Pasmant E, Gilbert-Dussardier B, Petit A, et al. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. Oncogene. 2015;34(5):631-8.
Pasmant, E., Gilbert-Dussardier, B., Petit, A., de Laval, B., Luscan, A., Gruber, A., Lapillonne, H., Deswarte, C., Goussard, P., Laurendeau, I., Uzan, B., Pflumio, F., Brizard, F., Vabres, P., Naguibvena, I., Fasola, S., Millot, F., Porteu, F., Vidaud, D., ... Ballerini, P. (2015). SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. Oncogene, 34(5), 631-8. https://doi.org/10.1038/onc.2013.587
Pasmant E, et al. SPRED1, a RAS MAPK Pathway Inhibitor That Causes Legius Syndrome, Is a Tumour Suppressor Downregulated in Paediatric Acute Myeloblastic Leukaemia. Oncogene. 2015 Jan 29;34(5):631-8. PubMed PMID: 24469042.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. AU - Pasmant,E, AU - Gilbert-Dussardier,B, AU - Petit,A, AU - de Laval,B, AU - Luscan,A, AU - Gruber,A, AU - Lapillonne,H, AU - Deswarte,C, AU - Goussard,P, AU - Laurendeau,I, AU - Uzan,B, AU - Pflumio,F, AU - Brizard,F, AU - Vabres,P, AU - Naguibvena,I, AU - Fasola,S, AU - Millot,F, AU - Porteu,F, AU - Vidaud,D, AU - Landman-Parker,J, AU - Ballerini,P, Y1 - 2014/01/27/ PY - 2013/04/30/received PY - 2013/11/11/revised PY - 2013/12/03/accepted PY - 2014/1/29/entrez PY - 2014/1/29/pubmed PY - 2015/4/11/medline SP - 631 EP - 8 JF - Oncogene JO - Oncogene VL - 34 IS - 5 N2 - Constitutional dominant loss-of-function mutations in the SPRED1 gene cause a rare phenotype referred as neurofibromatosis type 1 (NF1)-like syndrome or Legius syndrome, consisted of multiple café-au-lait macules, axillary freckling, learning disabilities and macrocephaly. SPRED1 is a negative regulator of the RAS MAPK pathway and can interact with neurofibromin, the NF1 gene product. Individuals with NF1 have a higher risk of haematological malignancies. SPRED1 is highly expressed in haematopoietic cells and negatively regulates haematopoiesis. SPRED1 seemed to be a good candidate for leukaemia predisposition or transformation. We performed SPRED1 mutation screening and expression status in 230 paediatric lymphoblastic and acute myeloblastic leukaemias (AMLs). We found a loss-of-function frameshift SPRED1 mutation in a patient with Legius syndrome. In this patient, the leukaemia blasts karyotype showed a SPRED1 loss of heterozygosity, confirming SPRED1 as a tumour suppressor. Our observation confirmed that acute leukaemias are rare complications of the Legius syndrome. Moreover, SPRED1 was significantly decreased at RNA and protein levels in the majority of AMLs at diagnosis compared with normal or paired complete remission bone marrows. SPRED1 decreased expression correlated with genetic features of AML. Our study reveals a new mechanism which contributes to deregulate RAS MAPK pathway in the vast majority of paediatric AMLs. SN - 1476-5594 UR - https://www.unboundmedicine.com/medline/citation/24469042/SPRED1_a_RAS_MAPK_pathway_inhibitor_that_causes_Legius_syndrome_is_a_tumour_suppressor_downregulated_in_paediatric_acute_myeloblastic_leukaemia_ L2 - https://doi.org/10.1038/onc.2013.587 DB - PRIME DP - Unbound Medicine ER -